While a skeptical Street continues to trade Caremark Rx Inc.’s $6 billion takeout of AdvancePCS wide, a legal source within the pharmacy benefit manager (PBM) sector and an antitrust partner experienced with healthcare deals anticipate the deal would fly.
To read the entire story, you must be logged in.
Please log in now or register with us.
